SEC Comment Letter 0000000000-22-012311 to Neptune Wellness Solutions Inc. (NEPTF) (CIK 0001401395)

Neptune Wellness Solutions Inc. (NEPTF) (CIK 0001401395)
Date: Nov. 11, 2022 · CIK: 0001401395 · Accession: 0000000000-22-012311

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-268196

Date

November 11, 2022

Author

John S. Wirt, Esq.

Form

UPLOAD

Company

Neptune Wellness Solutions Inc. (NEPTF) (CIK 0001401395)

Letter

United States securities and exchange commission logo November 11, 2022 John S. Wirt, Esq. General Counsel Neptune Wellness Solutions Inc. 545 Promenade du Centropolis Suite 100 Laval, Quebec, Canada H7T 0A3 Re:Neptune Wellness Solutions Inc. Registration Statement on Form S-1 Filed November 7, 2022 File No. 333-268196 Dear John S. Wirt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: François Paradis, Esq.

Show Raw Text

United States securities and exchange commission logo
November 11, 2022
John S. Wirt, Esq.
General Counsel
Neptune Wellness Solutions Inc.
545 Promenade du Centropolis
Suite 100
Laval, Quebec, Canada H7T 0A3
Re:Neptune Wellness Solutions Inc.
Registration Statement on Form S-1
Filed November 7, 2022
File No. 333-268196
Dear John S. Wirt:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635  with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       François Paradis, Esq.

SecProbe.io